Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.82% | 12.42% | 2.39% | 7.46% | -15.74% |
| Total Depreciation and Amortization | -31.96% | -23.03% | -16.36% | -7.60% | 3.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.57% | 18.46% | 67.93% | 60.86% | 389.99% |
| Change in Net Operating Assets | -91.06% | -58.21% | 59.94% | -203.94% | -110.21% |
| Cash from Operations | 13.66% | 16.05% | 17.75% | 9.81% | 7.10% |
| Capital Expenditure | -715.48% | -497.66% | -256.85% | 39.29% | 88.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 801.74% | 212.32% | 224.65% | -68.13% | -89.10% |
| Cash from Investing | 809.85% | 206.00% | 224.18% | -68.85% | -89.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -100.00% | 28,387.55% |
| Repurchase of Common Stock | -- | -- | -- | -270.00% | -270.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -78.10% | -68.41% | -79.69% | -74.64% | -- |
| Cash from Financing | -94.50% | -92.82% | -95.39% | -95.38% | 117,420.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 198.22% | 823.47% | 93.75% | -202.65% | 44.84% |